Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.15)
# 1,162
Out of 5,118 analysts
107
Total ratings
38.61%
Success rate
15.97%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $25.25 | +200.99% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.09 | +282.78% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.56 | +4,130.77% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.25 | +4,700.00% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.82 | +502.84% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $3.40 | +223.53% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $65.57 | -23.75% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.48 | +1,048.65% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $7.50 | +2,833.33% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.41 | +892.91% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $67 | $3.50 | +1,814.29% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $18.57 | +131.56% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.55 | +224.32% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.01 | +642.57% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.00 | +275.00% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $13.46 | +56.02% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.73 | +464.64% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.14 | +3,408.77% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $5.93 | +743.17% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $8.71 | +1,208.84% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.89 | +3,295.59% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.60 | +161.90% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $25.17 | +58.92% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.10 | +3,263.64% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $8.28 | +286.47% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $6.16 | +1,150.00% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.23 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $69.62 | -28.18% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.17 | +538.30% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.37 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $16.57 | +56.91% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $253.68 | -88.96% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.37 | +15,728.68% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.30 | +70.73% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $25.25
Upside: +200.99%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.09
Upside: +282.78%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.56
Upside: +4,130.77%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.25
Upside: +4,700.00%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.82
Upside: +502.84%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $3.40
Upside: +223.53%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $65.57
Upside: -23.75%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.48
Upside: +1,048.65%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $7.50
Upside: +2,833.33%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.41
Upside: +892.91%
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $3.50
Upside: +1,814.29%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $18.57
Upside: +131.56%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.55
Upside: +224.32%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.01
Upside: +642.57%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.00
Upside: +275.00%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $13.46
Upside: +56.02%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.73
Upside: +464.64%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.14
Upside: +3,408.77%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $5.93
Upside: +743.17%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $8.71
Upside: +1,208.84%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.89
Upside: +3,295.59%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.60
Upside: +161.90%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $25.17
Upside: +58.92%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.10
Upside: +3,263.64%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $8.28
Upside: +286.47%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $6.16
Upside: +1,150.00%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.23
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $69.62
Upside: -28.18%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.17
Upside: +538.30%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $15.37
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $16.57
Upside: +56.91%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $253.68
Upside: -88.96%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.37
Upside: +15,728.68%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.30
Upside: +70.73%